Aimmune Therapeutics, Inc., a pioneering biopharmaceutical company based in the United States, focuses on developing innovative treatments for food allergies. Founded in 2011, Aimmune has made significant strides in the industry, particularly with its flagship product, Palforzia, which is the first FDA-approved therapy for peanut allergy. This groundbreaking treatment offers a unique approach to desensitising patients, setting Aimmune apart in the competitive landscape of allergy therapeutics. With its headquarters in Brisbane, California, Aimmune operates primarily in North America and has established a strong market position through its commitment to research and development. The company’s dedication to advancing food allergy treatments has garnered recognition, positioning Aimmune as a leader in the biopharmaceutical sector.
We don't have data for Aimmune Therapeutics, Inc., but we can show you information about their parent organization instead.
View parent company